FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks
Publishing timestamp: 2023-02-28 19:20:23
Summary
The FDA's independent advisors recommended Pfizer's RSV vaccine for adults ages 60 and older, despite safety concerns after two trial participants developed Guillain-Barre syndrome. The FDA is expected to make its decision in May. The vaccine could prevent more than 5000 deaths, 68000 hospitalizations, 51000 emergency department visits and more than 422000 outpatient visits. However, there is still a lack of efficacy data on people with weak immune systems and nursing home residents.
Sentiment: MIXED
Tickers: PFE,
Keywords: business, epidemics, health care industry, business news, politics, breaking news: business, disease outbreaks, u.s. economy, pfizer inc, biotechnology, pandemics, biotech and pharmaceuticals, coronavirus,
Source: https://www.cnbc.com/2023/02/28/rsv-vaccine-fda-committee-votes-on-pfizer-shot-for-older-adults.html